Carolina Aguilar

HelloBetter is a European leader in the field of digital therapeutics (DTx) for mental health and a global pioneer in digital mental health research. Founded in 2015, HelloBetter has the strongest evidence base globally, with a total of 33 randomized controlled trials published in peer-reviewed journals. In Germany, six of their therapy programmes are part of the standard of care and as such available to 70+ million people for free as prescription digital therapeutics or DiGA. In 2022, HelloBetter entered the US market with its HelloGina brand which offers a sexual wellness program for people with vaginismus. In 2023, HelloBetter received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its digital therapeutic HelloBetter Panic.

Embla is a turnkey, digital weight care solution built for cost-conscious U.S. employers. We combine GLP-1 microdosing with expert psychology-based coaching to deliver 16.7% average weight loss in 12 months — using 55% less medication. That means better outcomes, fewer side effects, and lower costs. We handle everything end-to-end: providers, prescriptions, pharmacy, PBM, and employee onboarding. No admin burden. No health plan integration. Fully live in 7 days with simple, pay-per-active-member pricing. Founded in Denmark — the home of GLP-1 — Embla is trusted by U.S. health systems and self-funded employers. Our approach is validated by one of the largest real-world GLP-1 studies and supported by partnerships with the University of Copenhagen and biotech giant Novonesis. Affordable GLP-1 coverage starts here.

HelloBetter is a European leader in the field of digital therapeutics (DTx) for mental health and a global pioneer in digital mental health research. Founded in 2015, HelloBetter has the strongest evidence base globally, with a total of 33 randomized controlled trials published in peer-reviewed journals. In Germany, six of their therapy programmes are part of the standard of care and as such available to 70+ million people for free as prescription digital therapeutics or DiGA. In 2022, HelloBetter entered the US market with its HelloGina brand which offers a sexual wellness program for people with vaginismus. In 2023, HelloBetter received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its digital therapeutic HelloBetter Panic.

Embla is a turnkey, digital weight care solution built for cost-conscious U.S. employers. We combine GLP-1 microdosing with expert psychology-based coaching to deliver 16.7% average weight loss in 12 months — using 55% less medication. That means better outcomes, fewer side effects, and lower costs. We handle everything end-to-end: providers, prescriptions, pharmacy, PBM, and employee onboarding. No admin burden. No health plan integration. Fully live in 7 days with simple, pay-per-active-member pricing. Founded in Denmark — the home of GLP-1 — Embla is trusted by U.S. health systems and self-funded employers. Our approach is validated by one of the largest real-world GLP-1 studies and supported by partnerships with the University of Copenhagen and biotech giant Novonesis. Affordable GLP-1 coverage starts here.

High density and high resolution graphene intelligent neural systems for central and peripheral Neuroelectronic applications. *FDA breakthrough Designation* Pioneering Precision Neurology